Raquel Hladun Alvaro I hold a degree in Medicine and Surgery from the Universitat de Barcelona and completed my medical residency in Pediatrics and its Specific Areas at Vall d’Hebron University Hospital. I undertook a fellowship in Pediatric Oncology and Hematology at Vall d’Hebron Hospital in Barcelona and completed my training with a fellowship in new drug development at Gustave Roussy, an internationally renowned center for pediatric cancer treatment. Institutions of which they are part Predoctoral researcher Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Doctor Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital Email Raquel Hladun Alvaro Email Institutions of which they are part Predoctoral researcher Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Doctor Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital I hold a degree in Medicine and Surgery from the Universitat de Barcelona and completed my medical residency in Pediatrics and its Specific Areas at Vall d’Hebron University Hospital. I undertook a fellowship in Pediatric Oncology and Hematology at Vall d’Hebron Hospital in Barcelona and completed my training with a fellowship in new drug development at Gustave Roussy, an internationally renowned center for pediatric cancer treatment.
Since 2017, I have worked as a Consultant in the Pediatric Oncology Department at Vall d’Hebron Hospital. I am currently responsible for pediatric soft tissue sarcomas, pediatric liver tumors, and pediatric precision medicine. I am also part of the Childhood Cancer Research Group at the Vall d’Hebron Institute of Research (VHIR), where I actively participate in the Sarcoma Laboratory and the Personalized Medicine Program. I serve as the National Coordinator in Spain for the clinical trial FaR-RMS for newly diagnosed and relapsed patients, developed by the European Pediatric Soft Tissue Sarcoma Group (EpSSG). I lead the Soft Tissue Sarcoma Working Group of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP) and am an active member of the EpSSG Phase I/II Committee. I am also part of SEHOP’s Personalized Medicine Working Group and a member of the European consortium Innovative Therapies for Children with Cancer (ITCC). I participate as a co-investigator in major personalized medicine projects, such as the European program MAPPYACTS (MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification) and the national program SEHOP-PENCIL (Personalised mEdiciNe for Cancer in chILdren in Spain).
Projects Desarrollo de una nueva plataforma preclínica para evaluar y optimizar tratamientos de mantenimiento en el sarcoma de Ewing IP: Josep Roma Castanyer Collaborators: Raquel Hladun Alvaro, Júlia Sansa Girona, Lia Garcia Gilabert, Patricia Zarzosa Martinez, Lucas Moreno Martín-Retortillo Funding agency: Fundación Aless Lequio Funding: 50000 Reference: ALESSLEQUIO/PROJECTE/2025/ROMA Duration: 01/01/2026 - 31/12/2027 Desarrollo avanzado de terapias innovadoras contra los sarcomas infantiles: refinamiento del bloqueo farmacológico de los co-receptores de la Vía Hedgehog IP: Josep Roma Castanyer Collaborators: Guillem Pons Barcons, Raquel Hladun Alvaro, Júlia Sansa Girona, Lia Garcia Gilabert, Gabriela Guillén Burrieza, Patricia Zarzosa Martinez Funding agency: Instituto de Salud Carlos III Funding: 190000 Reference: PI24/00825 Duration: 01/01/2025 - 31/12/2027 Development of a novel and potent strategy for blocking the Hedgehog pathway to treat pediatric sarcomas IP: Josep Roma Castanyer Collaborators: Guillem Pons Barcons, Raquel Hladun Alvaro, Júlia Sansa Girona, Lia Garcia Gilabert, Patricia Zarzosa Martinez, Lucas Moreno Martín-Retortillo Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 20000 Reference: 2024 LLAV 00024 Duration: 02/12/2024 - 01/06/2025 Incorporación de terapias dirigidas e inmunoterapia para el tratamiento de niños y adolescentes con neuroblastoma en recaída mediante su caracterización genómica y el desarrollo del ensayo clínico aleatorizado fase 2 BEACON2. IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes, Aroa Soriano Fernández, Jessica Camacho Soriano, Lorena Valero Arrese, Raquel Hladun Alvaro, Gabriela Guillén Burrieza Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI24/01576 Duration: 01/01/2025 - 31/12/2027 Pagination Current page 1 Page 2 Page 3 Page 4 Next page › Last page »
